SkinMedica Lytera 2.0 Pigment Correcting Serum
Multi-target brightening with hexapeptide, tranexamic acid, and niacinamide
About This Treatment
SkinMedica Lytera 2.0 is an advanced brightening serum with multi-target approach without hydroquinone.
■ Hexapeptide complex: suppresses tyrosinase at gene expression level ■ Hexylresorcinol: melanin reduction (breaks down existing pigment) ■ Tranexamic acid: blocks UV-induced melanin via plasmin inhibition ■ Niacinamide: melanosome transfer inhibition + ceramide synthesis ■ Kojic acid: alternative depigmentation pathway
Validated in 10 clinical studies across 200+ subjects in US, Thailand, and Japan.
Mechanism of Action
Hexapeptide complex acts on TYR gene promoter to suppress tyrosinase mRNA transcription. Hexylresorcinol reduces/breaks down existing eumelanin. Tranexamic acid inhibits plasminogen→plasmin conversion, blocking UV→PGE2→MITF→tyrosinase cascade. Niacinamide attenuates PAR-2 signaling, inhibiting melanosome transfer 35-68%. Five mechanisms cover all stages of pigmentation.
Indications
Expected Results
10 clinical studies across 3 countries (200+ subjects): 100% reported visible results by 12 weeks. Statistically significant improvements at 4, 8, and 12 weeks. Some improvement visible as early as 2 weeks. Effective for stubborn hyperpigmentation.
Clinical Evidence
Risks & Side Effects
Low risk. No ochronosis risk (hydroquinone-free). Rare transient mild irritation. Safe for all skin types and tones. Sunscreen recommended.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition